Erlotinib
Erlotinib is a small-molecule tyrosine kinase inhibitor used in oncology as a targeted therapy against the EGFR.
Erlotinib is a small-molecule tyrosine kinase inhibitor used in oncology as a targeted therapy against the EGFR. By inhibiting EGFR signaling, erlotinib can reduce downstream pathways that promote tumor cell proliferation, survival, and migration. It is therefore commonly used as a reference EGFR inhibitor in medicinal chemistry and cancer pharmacology studies, especially in work focused on lung cancer and other EGFR-driven malignancies.
In recent biomedical research, erlotinib continues to serve both as a comparator drug and as a mechanistic probe for EGFR-dependent signaling. The publications provided here place it in studies of dual-target strategies, including EGFR/CDK-2 inhibition, EGFR/PARP-1 inhibition, and combination approaches with RAF inhibition or radiotherapy. These contexts reflect its role as a benchmark for potency and as part of broader efforts to improve targeted cancer therapy in diseases such as colorectal carcinoma, pancreatic cancer, diffuse intrinsic pontine glioma, and lung cancer.
Where the papers sit
9 papers from the last 6 months study erlotinib directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 1 human data · 8 preclinical
Themes no clear themes
Those 9 do not share a common subject.
-
Cancer therapeutics is the only broad link, spanning nanoliposome formulation, molecular profiling, computational modeling, clinical testing, and inhibitor discovery. Disease contexts range from EGFR-amplified solid tumors and resistant lung cancer to diffuse intrinsic pontine glioma. No shared mechanism, intervention, or endpoint recurs across the set. It therefore supports no common research direction.
Papers
The 9 papers from the last 6 months that study erlotinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (9)
- PMID 42032072
- PMID 41962189
- Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 23 Jul 2026 PMID 42492401
- scRADAR: Dissecting intratumoral drug response heterogeneity at single-cell resolution via mechanism-guided prototype routing. PLoS computational biology · 26 Jun 2026 PMID 42361193
- Multiscale modeling unveils molecular mechanisms of deep eutectic solvent-anticancer drug interactions for rational formulation design. International journal of pharmaceutics · 17 Jun 2026 PMID 42309199
- Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers. International journal of clinical oncology · 15 Jun 2026 PMID 42298055
- Structure-Based Design and Optimization of Novel PHGDH Inhibitors for Overcoming Erlotinib-Resistant Lung Cancer. Journal of medicinal chemistry · 9 Jun 2026 PMID 42263187
- Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. Drug development research · 28 May 2026 PMID 42207930
- Lead Discovery via Scaffold Refinement: Structure-Guided Optimization of 1,2,4-Triazolo[1,5-a]Pyrimidines as Potent Dual EGFR/CDK-2 Inhibitors Targeting Colorectal Carcinoma. Drug development research · 27 May 2026 PMID 42200498
By study type
Human data, design not indexed (1)
- Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers. International journal of clinical oncology · 15 Jun 2026 PMID 42298055
Preclinical: animal, cell and lab studies (8)
- Erlotinib Engineering Programs Tumor Targeting in an Atomically Precise Au8 Cluster. ACS nano · 20 Oct 2026 PMID 42899760
- Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 23 Jul 2026 PMID 42492401
- scRADAR: Dissecting intratumoral drug response heterogeneity at single-cell resolution via mechanism-guided prototype routing. PLoS computational biology · 26 Jun 2026 PMID 42361193
- Multiscale modeling unveils molecular mechanisms of deep eutectic solvent-anticancer drug interactions for rational formulation design. International journal of pharmaceutics · 17 Jun 2026 PMID 42309199
- A novel electrochemical sensing with MIP for highly selective and sensitive determination of anticancer drug erlotinib. Journal of pharmaceutical and biomedical analysis · 12 Jun 2026 PMID 42284916
- Structure-Based Design and Optimization of Novel PHGDH Inhibitors for Overcoming Erlotinib-Resistant Lung Cancer. Journal of medicinal chemistry · 9 Jun 2026 PMID 42263187
- Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. Drug development research · 28 May 2026 PMID 42207930
- Lead Discovery via Scaffold Refinement: Structure-Guided Optimization of 1,2,4-Triazolo[1,5-a]Pyrimidines as Potent Dual EGFR/CDK-2 Inhibitors Targeting Colorectal Carcinoma. Drug development research · 27 May 2026 PMID 42200498
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.